Jasper Therapeutics (JSPR) Cash from Financing Activities (2020 - 2025)

Jasper Therapeutics has reported Cash from Financing Activities for 6 years, with the latest figure at -$340000.0 in Q4 2025.

• On a quarterly basis, Cash from Financing Activities fell 198.55% year-over-year to -$340000.0 in Q4 2025; TTM through Dec 2025 was $28.4 million, a 40.69% decrease from a year earlier, with the FY2025 full-year figure at $34.2 million, down 28.55% from the prior year.
• Cash from Financing Activities was -$340000.0 for Q4 2025 at Jasper Therapeutics, down from $28.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $101.5 million in Q1 2023, with the low at -$909000.0 in Q4 2021.
• Average Cash from Financing Activities over 5 years is $15.4 million, with a median of $20500.0 recorded in 2022.
• The largest YoY upside for Cash from Financing Activities was 780753.85% in 2023 against a maximum downside of 2446.15% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$909000.0 in 2021, then jumped by 103.08% to $28000.0 in 2022, then tumbled by 1067.86% to -$271000.0 in 2023, then jumped by 227.31% to $345000.0 in 2024, then sank by 198.55% to -$340000.0 in 2025.
• The last three Cash from Financing Activities figures came in at -$340000.0 (Q4 2025), $28.4 million (Q3 2025), and $345000.0 (Q4 2024), per Business Quant data.